This bill amends Medicare’s statutory definitions and payment rules for home infusion therapy to preserve patient access and clarify congressional intent. It adds pharmacy services and several specific pharmacy tasks to the list of covered home-infusion services, allows nurse practitioners and physician assistants to establish and review home infusion plans of care, and updates payment rules that govern daily payments for infusion drugs and associated services.
The legislation also defines a class of ‘‘specified non-pump’’ IV antibacterial, antifungal, and antiviral drugs and guarantees payment for coordination and pharmacy services tied to those drugs even if the drug itself is not payable under Medicare Part B. Finally, it changes how Medicare pays for related supplies—preventing separate payment for certain HCPCS supply codes when those items are furnished the same day and tied to a home infusion therapy paid under the statute.
The changes take effect January 1, 2026.
At a Glance
What It Does
The bill amends sections of the Social Security Act to (1) add ‘‘pharmacy services’’ and specified pharmacy tasks to covered home infusion services; (2) modify the Medicare single-payment methodology for home infusion drug administration days (including a 5‑hour transitional rule and a 50% payment when the supplier is not physically present); (3) broaden who may establish and review a home infusion plan of care to include nurse practitioners and physician assistants; and (4) bar separate Medicare payment for specific supply HCPCS codes when paid under the home infusion payment.
Who It Affects
Medicare beneficiaries receiving home infusion; home-infusion pharmacies and suppliers; nurse practitioners and physician assistants who treat infusion patients; DME suppliers that bill supply codes A4221, A4222, and K0552; and CMS claims processing and program integrity units. Providers that administer non-pump IV antimicrobials will be directly affected by the billing clarifications.
Why It Matters
This is a targeted statutory fix that reshapes revenue flows for home infusion care—recognizing pharmacy work while consolidating payment for supplies and introducing payment reductions tied to supplier presence. Compliance officers, billing teams, and policy staff should expect changes to claims adjudication, documentation requirements, and supplier business models starting in 2026.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill rewrites parts of Medicare law to make it clearer that home infusion isn’t just nursing plus equipment: it explicitly adds pharmacy services and lists pharmacy tasks—assessments, drug preparation and compounding, coordination and documentation—as part of the covered home infusion bundle. That formal recognition affects which activities a qualified home infusion supplier can bill under the single-payment home infusion regime rather than as separate professional services.
On payment mechanics, the bill changes how a ‘‘day of infusion’’ is counted and priced. It instructs Medicare to treat each calendar day on which a drug is administered as a payable infusion day regardless of whether the supplier was physically in the patient’s home.
At the same time, it creates a distinct rule that, if the qualified home infusion supplier was not physically present on the day of administration, the single payment amount for that day is 50 percent of the otherwise applicable amount. For 2026–2029 the statute requires that the single‑payment amount reflect a five‑hour infusion-day assumption for each therapy; CMS must implement that transitional calculation.The bill creates a statutory category—‘‘specified non-pump drug or biological’’—to capture IV-administered antibacterial, antifungal, and antiviral drugs given without a durable‑medical‑equipment pump.
For those drugs the statute makes clear that suppliers can receive the home-infusion payment for the coordination and pharmacy services tied to the drug even if the drug itself would not be payable under Medicare Part B. That unblocks situations where the service bundle should be paid even though the product’s Part B payable status is uncertain.Finally, the measure stops duplicate billing for certain disposable supplies.
It adds a rule prohibiting payment under the general DME/supplies subsection for specific HCPCS codes (A4221, A4222, K0552) when those items are furnished the same day and tied to a home infusion therapy already paid under the home-infusion single-payment regime. In short: the bill consolidates several pieces of the home-infusion package into the single-payment pathway, recognizes pharmacy and non‑physician provider roles, and creates presence- and day-counting rules that will change revenue allocation for many suppliers.
The Five Things You Need to Know
The bill requires Medicare to treat each calendar day a home infusion drug is administered as a payable infusion day, even if the qualified supplier is not physically present that day.
If the qualified home infusion supplier is not physically present on the day the drug is administered, Medicare’s single payment for that day is 50% of the amount that would have applied if the supplier were physically present.
From January 1, 2026 through December 31, 2029, CMS must set the single payment amount so it reflects five hours of infusion per therapy per calendar day (a transitional rule).
The statute adds ‘‘pharmacy services’’ and specific tasks—assessments, drug preparation and compounding, coordination and documentation—to the definition of covered home infusion services, and allows nurse practitioners and physician assistants to establish and periodically review the home infusion plan of care.
Medicare will not separately pay under the DME/supplies subsection for HCPCS codes A4221, A4222, or K0552 (tubing, certain catheters and supplies) furnished the same day for the same home infusion drug already paid under the home infusion single-payment rule.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adds pharmacy services, permits NPs/PAs to manage plans of care, and revises day/payment rules
This section amends the statutory home‑infusion definitions to include ‘‘pharmacy services’’ and enumerates activities (assessments; drug preparation and compounding; coordination and documentation) as part of covered services. It also revises the plan‑of‑care rule to allow nurse practitioners and physician assistants to establish and periodically review the plan of care—placing them on par with physicians for these functions. On payment it modifies 1834(u) to (a) define an infusion administration calendar day as any day a drug is administered, (b) add a transitional instruction that CMS’s single‑payment calculation for 2026–2029 reflect five hours of infusion per day, and (c) create a new clause that reduces the single payment to 50% when the qualified home infusion supplier is not physically present in the home. Practically, this blends a daily counting rule that facilitates remote or asynchronous services with a statutory payment penalty when suppliers are not on site.
Defines a ‘‘specified non‑pump’’ drug category and guarantees payment for coordination services
This section creates a statutory carve‑out for IV drugs given without a durable pump that are antibacterial, antifungal, or antiviral (as categorized by the USP). By adding that definition and a billing clarification to 1834(u), the bill ensures that the coordination, pharmacy tasks, and other services described in the home‑infusion definition are payable under the home‑infusion payment pathway even if the drug product itself isn’t payable under Part B. The practical effect is to preserve payment for the service bundle in cases where device requirements would otherwise block Part B drug coverage, reducing a pathway that could have denied payment for pharmacy and coordination work tied to non‑pump antimicrobials.
Prevents separate Medicare payment for certain infusion supplies when bundled under home‑infusion payment
This section adds a special payment rule to the DME/supplies subsection that disallows separate payment for certain adjunct supply HCPCS codes (A4221, A4222, K0552, or their successors) furnished the same day and with respect to the same drug already paid under the home‑infusion single payment. The mechanics force claims adjudicators and suppliers to treat those supplies as part of the home‑infusion bundle (if the home infusion payment applies), preventing duplicate reimbursement. That change directly shifts revenue that some DME or supply vendors historically recognized into the home‑infusion payment stream and will require payers and suppliers to reconcile claims workflows.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries on home infusion — clearer statutory coverage for pharmacy coordination and explicit recognition of NP/PA roles should reduce care interruptions and expand clinician options for managing plans of care.
- Home‑infusion pharmacies and pharmacists — the statute explicitly recognizes pharmacy services and enumerates pharmacy tasks as covered activities under the home‑infusion payment, strengthening legal footing for billing those services as part of the infusion bundle.
- Nurse practitioners and physician assistants — statutory authorization to establish and periodically review home infusion plans of care expands clinical responsibility and billing opportunities for non‑physician clinicians.
- Suppliers furnishing IV antibacterial, antifungal, or antiviral therapies without pumps — the billing clarification ensures they can receive payment for coordination and pharmacy services even if the drug itself is not payable under Part B.
Who Bears the Cost
- DME and supply vendors that currently bill HCPCS codes A4221, A4222, and K0552 separately — they lose the ability to claim separate Medicare payment for those supplies when furnished the same day as a paid home infusion therapy.
- Home‑infusion suppliers that provide services without being physically present — the bill cuts the single payment for such days to 50%, which may reduce revenue for remote or asynchronous service models.
- Medicare Administrative Contractors and CMS — implementation requires system changes to adjudicate the new presence rule, apply the transitional five‑hour calculation, and suppress separate supply payments; that will create administrative and operational costs.
- Small or rural infusion providers — documentation and claims requirements to prove physical presence or coordinate bundled supply payment may disproportionately burden smaller operators with limited billing/IT resources.
Key Issues
The Core Tension
The bill wrestles with a classic trade‑off: expand and codify coverage to protect patient access and recognize pharmacy and non‑physician roles, while simultaneously consolidating and constraining payment to curb perceived overpayment. That creates a tension between ensuring providers receive enough revenue to sustain in‑person, high‑touch care and imposing payment rules (reduced pay when suppliers aren’t physically present; prohibition on separate supply billing) that could reduce incentives for in‑home staffing or shift costs onto small suppliers.
The bill tries to thread two policy goals—preserve patient access and rein in duplicative payments—but it leaves several implementation questions open. First, the statute ties payment reductions to whether a supplier was ‘‘physically present’’ in the home, but it does not define what documentation suffices to demonstrate presence or absence.
Claims processing will need clear audit rules to distinguish bona fide in‑home visits from remote monitoring, and suppliers will face exposure to recoupments if CMS later interprets presence narrowly.
Second, the transitional five‑hour infusion‑day assumption (2026–2029) simplifies payment calculation but risks mispricing therapies that commonly run shorter or longer than five hours. For shorter infusions it will overpay; for long continuous infusions it will underpay unless CMS adjusts therapy‑level rates.
The ban on separate payment for specific HCPCS codes also centralizes financial risk in the home‑infusion payment; if CMS’s single payment undercompensates suppliers for supplies, those suppliers will bear material cost shifts. Finally, the specified non‑pump drug definition is limited to antimicrobial categories; IV treatments outside those categories could remain in coverage limbo, creating uneven access depending on drug classification and USP categorization.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.